AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics



Hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC), this international conference, now in its 33rd year, attracts academics, scientists and pharmaceutical industry representatives from across the globe to discuss the novel cancer therapeutics, cancer drugs development, target selection, and the impact of new discoveries in cellular and molecular biology, and early clinical trials.

On the agenda:

  • Early phase trials to establish proof of concept for adoptive cellular therapy for solid tumors
  • Response adaptive randomization to prioritize promising investigational agents: I-SPY2
  • ctDNA and low dose CT for early-stage lung cancer screening: The SUMMIT Study
  • Exosome-driven suppression of the anti-tumor immune response
  • CRISPR and gene modification for cancer therapeutics
  • Bispecific T cell engagers and next-generation CAR T therapies: Pros and cons of these strategies
  • Targeting the DDR beyond PARP inhibitors: Novel agents and rational combinations
  • Mechanisms of acquired resistance to KRAS G12C inhibitors: Opportunities and challenges
  • Development on inhibitors of KRAS G12D
  • Discovery and development of RAS(ON) inhibitors beyond KRAS G12C
  • Clinical application of ctDNA in the MRD setting
  • Technical considerations in analyzing circulating DNA for the detection of the MRD and alternative methods based on cirDNA origin and topology
~ 2,500 participants

33.25 AMA PRA Category 1 Credits™

33.25 ABIM MOC points


October 7-10, 2021


Virtual Conference